Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium benzoate for treatment of attenuated/transient psychosis
2013-000458-23Phase 2Terminated
- Sponsor
- Niuvanniemi Hospital
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attenuated psychosis syndrome (APS) and Schizophrenia Spectrum Disorders (SSD) comparing Sodium benzoate with Placebo (2 arms). Primary endpoint: Clinical status. Started Mar 2013; status: terminated.
02
Drugs
sodium benzoate
03
Conditions
attenuated psychosis syndrome (APS)Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2013-000458-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000458-23.